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robust standard errors, and applied baseline sampling weights to
obtain estimates representative for the entire US population with
MS. For provider visits and amount of personal care (conditional
on using it), we estimated similar GLS Gaussian models with
logarithmic transformation of the number of services as depen-
dent variable. RESULTS: Use of most medical services increased
signiﬁcantly with the worsening of MS. However, patients with
severe MS (EDSS > 7.0) used the same or fewer services than
patients with EDSS 6.5–7 except for home health and personal
care. Having relapses signiﬁcantly increased use of most catego-
ries of health services. Longer time since diagnosis, after adjust-
ing for MS stage, was associated with a lower level of utilization
of ER, hospital outpatient care, therapy, and alternative medi-
cine. Patients who were not married generally used more services
than married patients. CONCLUSION: While MS places a sub-
stantial ﬁnancial burden on individuals as well as private and
public payers, use of speciﬁc categories of health services varies
signiﬁcantly with MS severity, presence of relapses, and availabil-
ity of informal help.
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OBJECTIVE: The population over 60 years old is increasing in
Mexico, and thus, the prevalence of chronic-degenerative dis-
eases such as the Parkinson’s Disease is increasing. The objective
of this study was to compare the cost-utility of the treatment with
pramipexol vs. the treatment with l-dopa/carbidopa and sus-
tained release l-dopa/carbidopa, from an institutional perspective
in Mexico. METHODS: A cost-utility analysis was performed
using a decision tree model that simulates the cost and Quality
Adjusted Life Years (QALYs) for a hypothetical cohort of
patients recently diagnosed with Parkinson’s Disease, consider-
ing development or not of dyskinesias throughout a temporary
horizon of four years. The utilities for each health state were
obtained from reports in international literature. The model also
considers changes in drug’s dosage or the possibility that the
patient received treatment with both drugs, according to the
response and associated adverse events. Only annual costs per
drug were considered for this analysis, as the rest of the costs are
similar for buyers. Costs were estimated using 2006 prices and
are expressed in US dollars (exchange rate of 10.9 pesos per US
dollar). RESULTS: It was estimated that a patient treated with
pramipexol would have 3.07 QALYs on average vs. 1.96 QALYs
for a patient treated with L-DOPA/carbidopa, and 1.98 QALYs
for sustained release L-DOPA/carbidopa. Annual costs associ-
ated with each treatment are $1177.50 for pramipexol, $225.60
for L-DOPA/carbidopa and $449.90 for sustained release
L-DOPA/carbidopa. The incremental cost per QALY gained was
$3441.70 for pramipexol vs. l-dopa/carbidopa and $2649.8 for
pramipexol compared with sustained release l-dopa/carbidopa.
CONCLUSION: In Mexico, the treatment with pramipexol is a
highly cost-effective alternative to manage Parkinson’s disease
considering the WHO cost-effectiveness threshold of 1GDP.
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OBJECTIVE: Compare annual indirect costs between privately
insured USA employees with multiple sclerosis (MS) and
matched employee controls. METHODS: Employees with 1
MS diagnosis (ICD-9-CM: 340.x) after January 1, 2002, ages
18–64 years, were selected from a privately insured claims data-
base containing disability data from 17 USA companies. Employ-
ees with MS were matched by age and gender to employee
controls without MS. All were required to have continuous
health coverage 3 months before MS diagnosis (baseline) and 12
months after (study period). Chi-squared tests were used to
compare baseline comorbidities and differences in indirect
resource use (disability and medically-related absenteeism). Wil-
coxon rank-sum tests were used for univariate comparisons of
mean disability and medically-related absenteeism days and asso-
ciated annual indirect costs during the study period. RESULTS:
Employees with MS (n = 989) averaged 44 years old, and 66%
were female. Compared with employee controls, employees with
MS had signiﬁcantly higher rates of mental health disorders and
other neurological disorders and physical disorders as measured
by the Charlson Comorbidity Index. Employees with MS were
more likely to have short-term or long-term disability compared
to employee controls (21.4% vs 5.2%, respectively; P < 0.0001),
resulting in a higher mean number of disability days per year
(29.8 vs 4.5, respectively, P < 0.0001). Employees with MS also
had a higher rate of medically-related absenteeism and associated
absenteeism days compared to employee controls. On average,
annual costs for disability were signiﬁcantly higher for employees
with MS ($3868) compared with employee controls ($414);
P < 0.0001. Medically-related absenteeism costs were also higher
for employees with MS compared with controls ($1901 vs
$1003, respectively; P < 0.0001). On average, total indirect
costs for employees with MS was $5769 compared with con-
trols, $1417 (P < 0.0001). CONCLUSION: Indirect costs of
employees with MS were >4 times those of employee controls.
Effective treatments may reduce the burden of this disease in the
workplace.
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OBJECTIVE: Migraines afﬂict about 30 million people in the
United States. Determining how migraineurs differ from non-
migraneurs from the viewpoint of health resource utilization may
provide insights that could lead to more effective care strategies.
The objective of this study is to compare resource utilization
between migraineurs and non-migraineurs. METHODS: Care-
mark administrative pharmacy and medical claims data were
analyzed in this study over a one year period. Individuals with at
least one migraine medical claim (ICD-9 of 346.xx) and one
triptan/ergot claim were used to identify participants with
Migraine. Propensity score matching was used to sample partici-
pants without migraine (controls) matched for age, gender, and
number of co-morbidities. Outcomes included number of visits
and expenditures associated with ofﬁce visits (MD), emergency
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